4/19, 7:37 PM (Source: TeleTrader)
more TeleTrader news


Chart for: CUREVAC N.V.   O.N.

CureVac applies for jab certification in Switzerland

German biopharmaceutical company CureVac N.V.'s Swiss subsidiary, CureVac Swiss AG, initiated a rolling submission for its mRNA-based COVID-19 vaccine, the CVnCoV, for authorization to be used in Switzerland, according to an official press release the company posted on Monday.

The application for the authorization process was submitted to Switzerland's medical surveillance authority Swissmedic, which will review the available data that CureVac provided on the jab before it is considered safe and effective for use. CureVac's Chief Business Officer and Chief Commercial Officer Antony Blanc stated that Curevac considers Switzerland an important market for both the second-generation COVID-19 vaccines and vaccines for infectious diseases, adding that the current Swiss rollout of CVnCoV jabs is "the next key step" in their "ongoing efforts for the European Union territory."

The Swiss federal government signed a contract with CureVac in February for the supply of 5 million doses of the CVnCoV vaccines, based on the delivery agreement between the company and the European Commission.

Breaking the News / IV